莱斯康制药 LXRX 深 沪
等待开盘 08-01 09:30:00 美东时间
1.07
+0.050
+4.90%
华盛通- 最 高1.105
- 今 开1.02
- 成交量 199.03万股
- 最 低 1.0108
- 昨 收 1.02
- 总市值 3.88亿
- 52周最高 2.175
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 0.2836
- 委 比 54.38%
- 总股本 3.63亿
- 历史最高 22.96
- 量 比 0.82
- 振 幅 9.24%
- 历史最低 0.2836
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Lexicon Pharmaceuticals announced they will release their second quarter 2025 financial results on August 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET. The webcast and archived version will be available on their website.
07-23 12:00
Lexicon Pharmaceuticals To Present New Data On Diabetic Nerve Pain Burden At ASPN 2025 Conference
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be
07-18 20:02
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Lexicon announced data from a study on diabetic peripheral neuropathic pain (DPNP) patients despite standard treatment, to be presented at the ASPN 2025 meeting. DPNP, a debilitating complication of diabetes affecting millions, often impacts daily life. Lexicon’s investigational drug, pilavapadin, a novel non-opioid treatment targeting AAK1, showed promising results in reducing DNP pain in Phase 2a trials. The company aims to raise awareness of D...
07-18 12:00
Lexicon Pharmaceuticals Received Notice Of 180-Calendar Day Extension To Regain Nasdaq Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/1062822/000106282225000035/lxrx-20250703.htm
07-03 21:14
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $4 price target.
06-24 19:44
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Lexicon Pharmaceuticals, Inc. will present data on sotagliflozin's ability to reduce hypoglycemic risks in type 1 diabetes across kidney function subgroups at the ADA Scientific Sessions on June 22. The company will also share topline results from the PROGRESS Phase 2b study evaluating pilavapadin for diabetic peripheral neuropathic pain. M. Belinda Hardin, PharmD, will present sotagliflozin data in a session focused on preventing hypoglycemia.
06-18 12:30
纳斯达克生物科技指数收涨超2%
成分股Oric Pharma收涨33.50%，Erasca涨32.73%，Tango Therapeutics涨20.10%表现第三。莱斯康制药（LXRX）则收...
05-30 04:44
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals, Inc. announced that its management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the company’s website. Lexicon is a biopharmaceutical company focused on discovering and developing innovative medicines through its Genome5000™ program, targeting diseases such as heart fai...
05-29 12:00
礼来、诺和诺德之后，下一代减肥药谁主沉浮？
（转自：药剂Talks） 下一代减肥药，正在加速崛起。 4月16日，恒瑞医药启动了siRNA新药HRS-5817用于治疗超重或肥胖的Ⅰ期临床试验。目前，全球范...
05-16 08:36
